Bio (BIO) Holder Fort Washington Investment Advisors INC Cut Its Holding as Stock Price Rose

Bio-Rad Laboratories, Inc. (NYSE:BIO) LogoInvestors sentiment increased to 1.46 in 2019 Q1. Its up 0.45, from 1.01 in 2018Q4. It is positive, as 29 investors sold BIO shares while 82 reduced holdings. 61 funds opened positions while 101 raised stakes. 17.40 million shares or 11.49% less from 19.66 million shares in 2018Q4 were reported. Arrowstreet Capital Ltd Partnership has invested 0.05% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Mutual Of America Capital Management Limited Liability Com reported 0.08% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Quantitative Systematic Strategies holds 0.07% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 944 shares. Segall Bryant And Hamill Limited Liability Co owns 24,854 shares. Parkside National Bank & Trust And invested in 10 shares or 0% of the stock. Jpmorgan Chase & Com holds 50,511 shares. Wellington Management Group Limited Liability Partnership invested 0% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Charles Schwab Invest Inc owns 114,073 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt Sys reported 3,548 shares. Goldman Sachs Group Inc reported 171,840 shares or 0.02% of all its holdings. New York State Common Retirement Fund has 42,100 shares for 0.02% of their portfolio. Moreover, Brown Brothers Harriman has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 136 shares. Plante Moran Financial Advsr Ltd Com invested in 23 shares or 0% of the stock. Inv Counselors Of Maryland Ltd Com owns 914 shares. Public Employees Retirement Association Of Colorado has invested 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO).

Fort Washington Investment Advisors Inc decreased its stake in Bio (BIO) by 12.73% based on its latest 2019Q1 regulatory filing with the SEC. Fort Washington Investment Advisors Inc sold 25,544 shares as the company’s stock rose 6.00% . The hedge fund held 175,158 shares of the capital goods company at the end of 2019Q1, valued at $53.54M, down from 200,702 at the end of the previous reported quarter. Fort Washington Investment Advisors Inc who had been investing in Bio for a number of months, seems to be less bullish one the $9.51B market cap company. The stock increased 1.04% or $3.3 during the last trading session, reaching $319.13. About 170,094 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 3.54% since August 15, 2018 and is uptrending. It has outperformed by 3.54% the S&P500.

Fort Washington Investment Advisors Inc, which manages about $44.90 billion and $8.90 billion US Long portfolio, upped its stake in Alphabet Class C by 2,674 shares to 224,400 shares, valued at $263.29M in 2019Q1, according to the filing. It also increased its holding in Western Alliance Bancorp (NYSE:WAL) by 105,700 shares in the quarter, for a total of 697,608 shares, and has risen its stake in Disney (NYSE:DIS).

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Finance.Yahoo.com which released: “Bio-Rad to Report Second-Quarter 2019 Financial Results – Yahoo Finance” on July 23, 2019, also Businesswire.com with their article: “Bio-Rad to Participate in the Bank of America Merrill Lynch Health Care Conference 2019 in May – Business Wire” published on April 23, 2019, Businesswire.com published: “Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019 – Business Wire” on January 03, 2019. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Seekingalpha.com and their article: “Bio-Rad finance chief to retire – Seeking Alpha” published on January 03, 2019 as well as Globenewswire.com‘s news article titled: “OncoCyte Announces Participation at the 2019 BIO International Convention – GlobeNewswire” with publication date: May 29, 2019.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 2 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories has $350 highest and $34000 lowest target. $343.33’s average target is 7.58% above currents $319.13 stock price. Bio-Rad Laboratories had 6 analyst reports since February 23, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Friday, March 1 by Barclays Capital. The firm has “Buy” rating by Deutsche Bank given on Friday, March 1.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.